November 8th 2020
The treatment landscape of relapsed/ refractory multiple myeloma has undergone rapid changes over the past 2 decades, with over a dozen drug approvals by the FDA.
September 8th 2020
Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.
August 20th 2020
Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.
November 26th 2019
Ajai Chari, MD, discusses the implementing quadruplet-regimens in transplant-eligible multiple myeloma.
November 21st 2019
Ajai Chari, MD, discusses transplant eligibility in multiple myeloma.
September 20th 2019
Ajai Chari, MD, discusses the use of selinexor in multiple myeloma treatment.
August 8th 2019
Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the use of frontline daratumumab (Darzalex) in transplant-eligible patients with multiple myeloma.
July 29th 2019
Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the phase III E3A06 study, which looked at the effects of lenalidomide in patients with smoldering myeloma.
June 14th 2019
Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.